-
Xabi Alonso appointed Chelsea manager on four-year deal
-
Mass Ukraine drone barrage kills 4 in Russia: Moscow
-
Gucci takes over New York's Times Square for fashion show
-
Lyles says 'well worth the journey' after winning 100m in Tokyo
-
Nepali duo break own records on Everest
-
North Korean women footballers land in South ahead of rare match
-
North Korean women footballers arrive in South Korea: AFP
-
Rousey demolishes Carano in MMA comeback fight
-
German 'chemical town' fears impact of industrial decline
-
Qantas flight diverted after man bites flight attendant
-
India scrambles to steady rupee as oil shock bites
-
McGregor to make UFC return with Holloway rematch
-
WHO declares international emergency as Ebola outbreak kills more than 80 in DR Congo
-
Crackdown in Southeast Asia pushes scam networks to Sri Lanka
-
'Geek' hangout to tourist draw: Japan's maid cafes
-
Spacecraft to probe how Earth fends off raging solar winds
-
Bulgaria's 'Bangaranga' wins Eurovision, with Israel second
-
Musk wants SpaceX to go public. Here's how it works
-
Big risks and rewards in upcoming IPOs at SpaceX, OpenAI, Anthropic
-
Pal in last duo could ease nerves for PGA leader Smalley
-
Ronaldo suffers more agony as Al Nassr lose 1-0 in AFC final
-
Venezuela expels Maduro ally Alex Saab to US again
-
Rising star Woad in charge at LPGA Queen City Championship
-
Rodgers returning with Steelers for 22nd season
-
Rahm on PGA: 'It's a battle out there'
-
Dara: dancing to victory at Eurovision
-
As U.S. Markets Continue Surging to Historic All-Time Highs, ELEKTROS Believes This Could Be a Defining Opportunity for Penny Stock Investors Seeking Exposure to the Future of Lithium Mining, EV Infrastructure, and Next-Generation Electrification Technologies
-
Napoleon Solo wins 151st Preakness Stakes
-
Last 10 Eurovision winners
-
Smalley grabs PGA lead as wild final day showdown looms
-
Canada cruise passenger 'presumptive positive' for hantavirus
-
Five share PGA lead logjam with wild final day in store
-
Decision time at full-throttle Eurovision final
-
McIlroy charges into the hunt for epic major comeback win
-
Iran confirms squad heading to Turkey for World Cup preparation
-
Bolivian police clash with protesters blocking roads
-
Eurovision final kicks off with Viennese grandeur
-
Svitolina sees off Gauff to win Italian Open, Sinner in men's title showdown
-
Alonso set for appointment as Chelsea manager: reports
-
Spanish star Javier Bardem says 'narrative changing' on Gaza
-
Gujarat miss out on top spot as Kolkata stay alive in IPL
-
Charging McIlroy grabs share of the PGA lead
-
Rwanda genocide suspect Kabuga dead: court
-
No beer for City stars despite FA Cup win, says Guardiola
-
Modi oversees semi-conductor deal on Dutch trip
-
Americans 'should demonstrate like the French,' says Woody Harrelson
-
Vienna abuzz for Eurovision final
-
McFarlane eyes 'massive' Spurs clash after FA Cup final defeat
-
Scuffles from Europe to NYC as Swatch sale descends into chaos
-
Bielle-Biarrey helps Bordeaux-Begles avoid Top 14 slip-up before Champions Cup final
US tells pharmas to make Covid boosters targeting BA.4 and BA.5
The US Food and Drug Administration on Thursday told vaccine makers that Covid boosters for this fall and winter should include components targeting the BA.4 and BA.5 sublineages of Omicron.
Earlier this week, a panel of medical experts convened by the agency voted in favor of updating Covid vaccines against Omicron, with most indicating they would favor shots that target the latest iterations rather than its original form, BA.1, fearing the latter would be too out-of-date.
BA.4 and BA.5, which are more transmissible and immune evasive, now comprise more than 52 percent of US Covid cases, according to an official tracker.
"We have advised manufacturers seeking to update their Covid-19 vaccines that they should develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine," the FDA said in a statement.
These vaccines would also need to target the original Wuhan strain, in order to increase the breadth of immune response.
Pfizer and Moderna, which produce messenger RNA Covid vaccines, have developed and tested vaccines against BA.1, and representatives of both companies indicated during the experts' meeting they would need around three months to produce BA.4 and BA.5 vaccines at scale.
Pfizer shared early results showing its BA.4/5 vaccine produced a strong antibody response in mice, but it hasn't yet been trialed in humans.
Novavax, which makes a protein subunit vaccine, said it could offer BA.4/5 vaccines by the end of the year.
The FDA said in its new statement that the companies would need to submit human data prior to authorization.
The "primary series" or first shots a person receives would remain against the original strain, the FDA added.
While previous "variants of concern" like Alpha and Delta eventually petered out, Omicron and its sublineages have dominated throughout 2022, to the point it comprises the vast majority of all Covid in the world, FDA official Jerry Weir told the expert meeting this week.
This makes it more likely that the virus's future evolution will also occur along the Omicron branch of the Covid family tree, he added.
Earlier this month, the World Health Organization also recommended the use of Omicron boosters after a primary series against the original strain.
D.Sawyer--AMWN